DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Vadimezan is an investigational drug.
There have been 4 clinical trials for Vadimezan. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2010.
The most common disease conditions in clinical trials are Small Cell Lung Carcinoma, Lung Neoplasms, and [disabled in preview]. The leading clinical trial sponsors are Novartis Pharmaceuticals, Swiss Group for Clinical Cancer Research, and University of Glasgow.
Recent Clinical Trials for Vadimezan
|Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer||Swiss Group for Clinical Cancer Research||Phase 2|
|Safety and Pharmacokinetics of ASA404 When Given Together With Fluvoxamine, a Selective Serotonin Receptor Reuptake Inhibitor and CYP1A2 Inhibitor||Novartis Pharmaceuticals||Phase 1|
|Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors||Novartis Pharmaceuticals||Phase 1|